Fundamental Data for NABI

Nabi Biopharmaceuticals is a vertically integrated company committed to unlocking the power of the human immune system to help people with serious, unmet medical needs. The company has a broad product portfolio and significant research capabilities focused on the development and commercialization of drugs that prevent and treat infectious and autoimmune diseases.

# Employees: 40

Address: 5800 Park of Commerce Boulevard N.W.,Boca Raton,FL,USA

Phone: 561 989-5800

Fax: 561 989-5801

Website: www.nabi.com

Email: irpr@nabi.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Thomas H. McLain (Chmn.; Presi.; C.E.O.)

Mark L. Smith (Sr. V.P.; Fin.; C.F.O.; Chief Acctg. Off.; Treas.)

Henrik S. Rasmussen Ph.D. (Sr. V.P.; Clinical; Medical. & Regulatory Aff.)

Raafat E.F. Fahim Ph.D. (Sr. V.P.; Research; Techl. & Prodn. Opera.)

Joseph Johnson (Sr. V.P.; People; Process & Technology,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 3/10/2010

Mean EPS (Next Qtr): ($0.01)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 0

Shares Performance

Period	NABI	Compare to S&P
YTD	46.27 %	21.06 %
4 Weeks	49.85 %	48.23 %
12 Weeks	58.06 %	49.02 %

Shares Information

Analyst Coverage: N

Avg Volume: 611016

Shares Outstanding: 50M

Market Cap: $0.25B

52 Week High: $5.15

52 Week Low: $2.22

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 NABI split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: -27.27 %

EPS Growth in Last Year: -75.00 %

Sales Growth in Last Quarter: -0.01 %

Financials

Qtr Book Value: $2.50

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010